2016 - 2017
In 2016-17, Mankind Pharma expanded its horizon by launching the operations in US market. Company has on boarded Shruti Hassan as a brand endorser of Acnestar and chosen Sania Mirza to endorse Kaloree-1 brand. Again Manforce condoms is No 1 brand with revenue of Rs. 2550 million.(Source: As per A.C. Nielsen report May, 2016.)
2015 - 2016
In 2015-16, Mankind Pharma launched “Dynaglipt” that belongs to a novel class of DPP-4 Inhibitors- Gliptins. A break through achievement in Anti-Diabetic segment at most affordable price of Rs 7.90 to reach masses. This year Mankind achieved a turnover of 40000 million.
2014 - 2015
In 2014-15, Mankind achieved a sales turnover of Rs.35000 million. The year also witnessed the successful launch of HEALTH OK generating a revenue of Rs.500 million in one year. Another achievement this year was the rise of Manforce condoms, as we generated revenue worth more than Rs.2250 million, with market share of around 27 %.(Source: As per A.C. Nielsen report Dec,2014.)
2013 - 2014
In 2013-14, Mankind achieved a sales turnover of Rs.30000 million with a growth of 25.89%. The year also witnessed Mankind marking its presence in CIS countries such as Uzbekistan and Tajikistan as well as Ukraine and Ethiopia. In GCC, Mankind initiated its products in Bahrain. The company became the 7th largest pharmaceutical company in India as per IMS Health and also retained its No.1 rank in the number of prescriptions as per the PDM Audit.
2012 - 2013
Within a year, Mankind’s sales reached Rs.23820 million at a growth of 24.83%. In 2012-2013, Mankind extended its international reach to countries like Bangladesh, Nepal, Mauritius, Nigeria, Kenya, Zambia, Vietnam, Rwanda, Tanzania and Uganda. The year also saw Mankind’s field force reach 8500.
2011 - 2012
By 2011-2012, Mankind’s revenue grew by 20.21% to Rs.19090 million in sales. The company launched Lifestar 2 Pharma and set up a R&D Centre in Manesar. Mankind also expanded its operations to the Philippines.
2010 - 2011
In 2010, Mankind launched Pet Mankind and began its international operations in Sri Lanka. The company’s Y-O-Y growth increased by 52.25% and generated a total of Rs.15880 million in sales. Mankind’s R&D and Learning and Development Centre were also established. Mankind successfully acquired Longifene, a former brand of UCB Belgium and established the CSR wing of Mankind - Care Mankind. Mankind also successfully launched OTC products like Adiction and Gas-O-Fast. The company became the 8th largest pharmaceutical company in Indian as per IMS Health and also retained its No.1 rank in the number of prescriptions as per the PDM Audit. The company had 60 brands place in the top five positions, with 28 brands at No.1 and 22 brands at No. 2 position.
2009 - 2010
In 2009-2010, Mankind’s turnover grew by 28.45% to Rs.10430 million. The company ranked first in India as per ‘Value Generated from New Launches’ and established a state-of-the-art manufacturing unit for liquid dosages and tablets.
2008 - 2009
In 2008-2009, Mankind grew by 31%, generating Rs.8120 million in sales. The company also entered the top 10 domestic rankings and placed first in India as per PDM Audit. Mankind was certified as the Most Potential and ‘A’ Grade Vendor in Supply Chain Management by HINDALCO (the Aditya Birla Group). The company ranked 3rd and 4th in North India and India, respectively, as per IMS Health and Stockist Secondary Audit. 53 Mankind brands were placed in the top 5 positions, of which 21 were in No.1 position and 14 were in No.2 position, as per IMS Health and Stockist Secondary Audit.
2007 - 2008
Mankind’s success increased further by 27% in the next 2007-08, generating a total of Rs.6180 million in sales. The company achieved a number of milestones like acquiring Neuro-Psychiatry Focused Magnet and entering the OTC segment through the launch of Special Mankind and its flagship brands Manforce, PregaNews and Unwanted-72. Future Mankind and Vet Mankind were launched in the same year. Along with partnering with Chrys capital as an investor, the company was bestowed with ‘Emerging Company of the Year’ at the Pharma Excellence Award.
2006 - 2007
By 2006-2007, Mankind’s Y-O-Y grew by 44%, generating Rs. 4860 million in sales. The company also established a state-of-the-art Parental Unit at Paonta Sahib, Himachal Pradesh.
2005 - 2006
Within a decade, Mankind generated sales up to Rs.3380 million and had a Year-On-Year (Y-O-Y) growth of 61%. During 2005-2006, Mankind entered into chronic segments and launched Lifestar Pharma for segments like Antibacterial, Dermal, Gynaecological and Ophthalmic. The company celebrated ‘Decade of Trust’ with the medical fraternity and also won the Indian Express Pharma Pulse Award for ‘Overall Best Performance’.
1995 - 2002
Mankind was founded in 1995 and its products were launched in two states. In 2002, Mankind established operations throughout India. The company also launched a new segment, Discovery Mankind, which looked after segments like Diabetic, Metabolic Disorders, Antibiotics, Gastro-intestinal and Anti-fungal.